South Korea Orphan Drugs Market Report by Drug Type (Biological, Non-Biological), Disease Type (Oncology, Hematology, Neurology, Cardiovascular, and Others), Phase (Phase I, Phase II, Phase III, Phase IV), Top Selling Drugs (Revlimid, Rituxan, Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores, and Others), and Region 2024-2032

South Korea Orphan Drugs Market Report by Drug Type (Biological, Non-Biological), Disease Type (Oncology, Hematology, Neurology, Cardiovascular, and Others), Phase (Phase I, Phase II, Phase III, Phase IV), Top Selling Drugs (Revlimid, Rituxan, Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A21486
Buy Now

Market Overview:

South Korea orphan drugs market size is projected to exhibit a growth rate (CAGR) of XX% during 2024-2032. The launch of favorable policies by government bodies to inhibit the spread of contagious diseases is primarily driving the regional market.

Report Attribute
 Key Statistics                   
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Growth Rate (2024-2032) XX%


Orphan drugs are pharmaceutical products designed for the diagnosis, prevention, and treatment of rare medical disorders. These drugs are specifically developed to address a particular public health need and typically have a limited market due to their production for a small patient population. They prove effective against a range of conditions, including oncological, metabolic, hematologic, immunologic, infectious, and neurological diseases. Conditions such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma, and renal cell carcinoma fall under the category of orphan drug applications. These medical conditions are often characterized by being life-threatening, chronic, progressive, degenerative, and disabling, necessitating tailored treatment options that are effective in addressing their unique symptoms.

South Korea Orphan Drugs Market Trends:

The South Korea orphan drugs market has emerged as a critical component within the nation's healthcare landscape, addressing the specific medical needs of individuals affected by rare disorders. The regional market offers effective solutions against a spectrum of medical conditions, encompassing oncological, metabolic, hematologic, immunologic, infectious, and neurological diseases. Additionally, conditions, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma, and renal cell carcinoma fall under the ambit of orphan drug applications. Moreover, these medical disorders often present life-threatening, chronic, progressive, degenerative, and disabling characteristics, necessitating specialized treatment alternatives that can effectively address their distinctive symptoms. Besides this, as South Korea continues to advance in healthcare innovation, the orphan drugs market becomes integral in providing targeted and efficacious solutions for patients facing rare medical challenges. The focus on precision medicine and tailored treatments aligns with the nation's commitment to delivering advanced healthcare solutions. The South Korea stands as a pivotal player in the provision of specialized therapies that enhance the quality of life for individuals grappling with rare disorders, which is expected to fuel the regional market in the coming years.

South Korea Orphan Drugs Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on drug type, disease type, phase, top selling drugs, and distribution channel.

Drug Type Insights:

South Korea Orphan Drugs Market

  • Biological
  • Non-Biological
     

The report has provided a detailed breakup and analysis of the market based on the drug type. This includes biological and non-biological.

Disease Type Insights:

  • Oncology
  • Hematology
  • Neurology
  • Cardiovascular
  • Others
     

A detailed breakup and analysis of the market based on the disease type have also been provided in the report. This includes oncology, hematology, neurology, cardiovascular, and others.

Phase Insights:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV
     

The report has provided a detailed breakup and analysis of the market based on the phase. This includes phase I, phase II, phase III, and phase IV.

Top Selling Drugs Insights:

  • Revlimid
  • Rituxan
  • Copaxone
  • Opdivo
  • Keytruda
  • Imbruvica
  • Avonex
  • Sensipar
  • Soliris
  • Others
     

A detailed breakup and analysis of the market based on the top selling drugs have also been provided in the report. This includes revlimid, rituxan, copaxone, opdivo, keytruda, imbruvica, avonex, sensipar, soliris, and others.

Distribution Channel Insights:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Others
     

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, online stores, and others.

Regional Insights:

South Korea Orphan Drugs Market by Region

  • Seoul Capital Area
  • Yeongam (Southeastern Region)
  • Honam (Southwestern Region)
  • Hoseo (Central Region)
  • Others
     

The report has also provided a comprehensive analysis of all the major regional markets, which include Seoul Capital Area, Yeongam (Southeastern Region), Honam (Southwestern Region), Hoseo (Central Region), and Others.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

South Korea Orphan Drugs Market Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Million
Scope of the Report Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
  • Drug Type
  • Disease Type
  • Phase
  • Top Selling Drugs
  • Distribution Channel
  • Region
Drug Types Covered Biological, Non-Biological
Disease Types Covered Oncology, Hematology, Neurology, Cardiovascular, Others
Phases Covered Phase I, Phase II, Phase III, Phase IV
Top Selling Drugs Covered Revlimid, Rituxan, Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, Others
Distribution Channels Covered Hospital Pharmacies, Retail Pharmacies, Online Stores, Others
Regions Covered Seoul Capital Area, Yeongnam (Southeastern Region), Honam (Southwestern Region), Hoseo (Central Region), Others
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3699
Five User License: US$ 4699
Corporate License: US$ 5699
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report:

  • How has the South Korea orphan drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the South Korea orphan drugs market?
  • What is the breakup of the South Korea orphan drugs market on the basis of drug type?
  • What is the breakup of the South Korea orphan drugs market on the basis of disease type?
  • What is the breakup of the South Korea orphan drugs market on the basis of phase?
  • What is the breakup of the South Korea orphan drugs market on the basis of top selling drugs?
  • What is the breakup of the South Korea orphan drugs market on the basis of distribution channel?
  • What are the various stages in the value chain of the South Korea orphan drugs market?
  • What are the key driving factors and challenges in the South Korea orphan drugs?
  • What is the structure of the South Korea orphan drugs market and who are the key players?
  • What is the degree of competition in the South Korea orphan drugs market?

Key Benefits for Stakeholders:

  • IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the South Korea orphan drugs market from 2018-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the South Korea orphan drugs market.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the South Korea orphan drugs industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
South Korea Orphan Drugs Market Report by Drug Type (Biological, Non-Biological), Disease Type (Oncology, Hematology, Neurology, Cardiovascular, and Others), Phase (Phase I, Phase II, Phase III, Phase IV), Top Selling Drugs (Revlimid, Rituxan, Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores, and Others), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More